Key Insights• According to the research report, "Saudi Arabia EPA & DHA Market Outlook, 2031," published by Actual Market Research, the Saudi Arabia EPA & DHA Market is anticipated to grow at more than 7.43% CAGR from 2026 to 2031.The Saudi Arabian EPA & DHA market is expanding steadily as the Kingdom faces a high burden of cardiometabolic disease, a young and rapidly growing population, and a healthcare transformation under Vision 2030 that is placing prevention and wellness at the center of national health policy. According to the General Authority for Statistics (GASTAT), Saudi Arabia's population reached approximately 35.3 million at the end of 2024, up 4.7% from 33.7 million in 2023, with Saudi nationals accounting for about 19.6 million, or 55.6%, and non-Saudis about 15.7 million, or 44.4%. The population is young, with 22.5% aged 0–14 and only 2.8% aged 65 and older, but lifestyle-related conditions such as obesity, diabetes, dyslipidemia, and hypertension are highly prevalent and cardiovascular disease remains a leading cause of death. Low intake of oily fish among large parts of the population, combined with sedentary lifestyles and high consumption of processed foods, is creating a structural gap in dietary EPA and DHA. The growing clinical burden is placing additional pressure on the Ministry of Health, the Saudi Health Holding Company, and the consumer health sector to strengthen access to EPA and DHA through supplements, prescription medicines, infant nutrition, and fortified foods.• Saudi Arabia's EPA & DHA market is characterized by a fast-modernizing ecosystem comprising international supplement brands, domestic pharmaceutical manufacturers, large pharmacy chains, hypermarkets, e-commerce platforms, and dairy and infant nutrition producers. Pharmacy chains such as Nahdi Medical Company and Al-Dawaa Medical Services operate extensive pharmacy networks across the Kingdom and serve as the primary channels for omega-3 supplements, alongside hypermarkets, health stores, and online platforms such as Noon, Amazon.sa, and pharmacy delivery apps.

Domestic pharmaceutical manufacturers such as SPIMACO, Jamjoom Pharma, and Tabuk Pharmaceuticals are expanding local production under Vision 2030 localization targets, while dairy and food companies such as Almarai have built infant and clinical nutrition capabilities. International brands from the U.S., Europe, Canada, and Australia dominate the omega-3 supplement category, with growing demand for halal-certified and premium formats.• Regulatory oversight for EPA and DHA products is administered by the Saudi Food and Drug Authority (SFDA), which regulates food supplements, health products, medicines, and foods. Food supplements, including omega-3 capsules and liquids, must be registered with the SFDA before marketing, under a framework that expanded the scope of food supplements to include orally administered products such as capsules and tablets. Prescription omega-3 medicines require SFDA marketing authorization, and infant formula must comply with SFDA and GCC technical regulations. In February 2026, the SFDA notified the World Trade Organization of a draft technical regulation updating the types and amounts of vitamins and minerals permitted in fortified foods, including minimum and maximum nutrient ranges for infant formula and young children's foods, and prohibiting fortification that could mislead consumers about nutritional value. Halal requirements and Arabic labelling apply to all products.Market Outlook• A defining characteristic of Saudi Arabia's EPA & DHA market is the rapid transformation of healthcare and consumer health under Vision 2030.

The Health Sector Transformation Program is shifting the system toward prevention, primary care, and digital health, while promoting physical activity and healthier lifestyles through national initiatives. This is increasing awareness of cardiovascular risk management and supporting physician and pharmacist recommendation of omega-3 supplements. Consumers are shifting from basic fish oil products toward high-concentration triglyceride oils, krill oil, algal DHA, and children's formats, with e-commerce and pharmacy delivery apps expanding access across the Kingdom. The SFDA's structured registration framework for food supplements is improving product quality and consumer trust, while encouraging international brands to establish formal distribution partnerships.• The market also reflects Saudi Arabia's growing emphasis on maternal and child health. With 22.5% of the population aged 0–14, demand for DHA-fortified infant formula, growing-up milks, children's supplements, and prenatal products remains strong. The SFDA's draft fortification regulation notified in February 2026 is expected to update compositional requirements for infant formula and young children's foods, shaping product formulation by domestic and multinational manufacturers.

Simultaneously, the expansion of private healthcare, mandatory health insurance for expatriates, and the growth of sports and fitness culture among younger Saudis are broadening the consumer base for EPA and DHA products beyond traditional cardiovascular positioning.Market DynamicsDriver: High cardiometabolic disease prevalence and Vision 2030 health transformationSaudi Arabia's EPA & DHA market is primarily driven by the high prevalence of obesity, diabetes, dyslipidemia, and hypertension, which elevate cardiovascular risk across a large share of the adult population. Cardiovascular disease remains a leading cause of death in the Kingdom, and lifestyle-related conditions are developing at relatively young ages. Rapid population growth, reaching approximately 35.3 million at the end of 2024, is expanding the consumer base, while rising incomes and health awareness support spending on supplements. Vision 2030's Health Sector Transformation Program prioritizes prevention and healthy lifestyles, encouraging physicians, pharmacists, and nutritionists to recommend omega-3 for cardiovascular, cognitive, and joint health. As awareness of preventive health continues to grow, pharmacies and e-commerce platforms are witnessing sustained demand for EPA and DHA products.Challenge: Import dependence, registration requirements, and low baseline awareness in some segmentsOne of the principal challenges facing Saudi Arabia's EPA & DHA market is its dependence on imported finished products and ingredients, which exposes the market to global supply disruptions and raw material price volatility. Peru's first 2026 north-central anchovy quota was set approximately 36% lower than in 2025, following a coastal El Niño event, while the Antarctic krill fishery closed early in both 2025 and 2026.

SFDA registration, halal certification, and Arabic labelling requirements extend time to market for international brands, particularly smaller companies without established local partners. Additionally, awareness of the specific benefits of EPA and DHA remains uneven across regions and income groups, and the young age profile of the population means that cardiovascular prevention messaging must reach consumers earlier in life. Together, these factors contribute to premium pricing and slower penetration outside major cities.Trend: Local manufacturing, e-commerce growth, and expansion of maternal and child nutritionSaudi Arabia is experiencing a significant shift toward localized production and digital distribution of health products supported by Vision 2030 industrial and healthcare localization goals. Domestic pharmaceutical and nutrition companies are expanding manufacturing capabilities, including softgel and supplement production, while international brands are partnering with local distributors and manufacturers. E-commerce and pharmacy delivery apps are expanding access to omega-3 supplements in Riyadh, Jeddah, Dammam, and smaller cities. Simultaneously, the strong demographic base of children and young families is supporting demand for DHA-fortified infant formula, children's omega-3 gummies, and prenatal supplements.

The growing popularity of fitness and sports nutrition among younger Saudis is also boosting demand for EPA-rich products positioned for recovery and joint health, while halal-certified fish gelatin and plant-based algal omega-3 capsules are gaining share.Policies• SFDA Food Supplement Registration: Food supplements containing EPA and DHA must be registered with the SFDA before marketing. The SFDA's framework covers orally administered supplements such as capsules, tablets, and liquids, with requirements for composition, safety, labelling, and manufacturing quality.• SFDA Medicine Authorization: Prescription omega-3 medicines require SFDA marketing authorization under the Law of Pharmaceutical and Herbal Establishments and Products, including evidence of quality, safety, and efficacy and compliance with Good Manufacturing Practice.• Draft Fortification Technical Regulation (2026): Notified to the WTO in February 2026, the SFDA's draft regulation updates the types and amounts of vitamins and minerals allowed in fortified foods, sets nutrient ranges for infant formula and young children's foods, and prohibits misleading fortification and claims that a balanced diet is insufficient.• GCC Standards, Halal, and Labelling Requirements: Omega-3 products and fortified foods must comply with GCC Standardization Organization technical regulations, halal requirements for ingredients such as gelatin capsules, and Arabic labelling rules.• Vision 2030 Health Sector Transformation Program: The program restructures healthcare delivery toward prevention, primary care, and digital health, supporting national initiatives that promote healthy lifestyles and chronic disease management, providing a policy backdrop for evidence-based nutritional interventions.Segment AnalysisSaudi Arabia EPA & DHA Market By Product Type• Docosahexaenoic Acid (DHA) maintains an important position within Saudi Arabia, particularly in infant formula, growing-up milks, prenatal supplements, and children's products, supported by a population in which 22.5% are aged 0–14.• Eicosapentaenoic Acid (EPA) represents the fastest-growing product type segment in Saudi Arabia, driven by physician recommendation of high-EPA concentrates and omega-3 medicines for triglyceride management in a population with high rates of diabetes and dyslipidemia.Saudi Arabia EPA & DHA Market By Source• Fish Oil represents the leading revenue-generating source category in Saudi Arabia due to its broad consumer familiarity and the dominance of international fish oil brands in pharmacies.• Algae Oil maintains a growing position within Saudi Arabia, particularly in infant formula, prenatal products, and plant-based halal-friendly capsules.• Krill Oil is a premium source category sold primarily through pharmacies and e-commerce to higher-income consumers.• Other Marine Sources hold a niche position in the Saudi market, including cod liver oil and salmon oil, primarily used in children's supplements and pet nutrition.Saudi Arabia EPA & DHA Market By Application• Dietary Supplements represent the largest application segment in Saudi Arabia, distributed through pharmacy chains such as Nahdi and Al-Dawaa, hypermarkets, and e-commerce platforms.• Pharmaceuticals represent an important application segment, including prescription omega-3 medicines for hypertriglyceridemia and cardiovascular risk management, with domestic manufacturers expanding local production.• Infant Formula represents a strategically important application segment, with DHA widely included in formulas, supported by a young population and the SFDA's evolving compositional requirements.• Food & Beverages encompasses omega-3-enriched dairy, eggs, and functional foods, regulated under SFDA and GCC standards and the forthcoming fortification regulation.• Clinical Nutrition & Medical Foods includes enteral and parenteral nutrition products containing fish oil, used in public and private hospitals as healthcare capacity expands under Vision 2030.• Pet Nutrition represents the fastest-growing application segment in Saudi Arabia from a small base, supported by rising pet ownership among younger Saudis and expatriates and the growth of specialty pet retail.Major EPA & DHA Manufacturers Operating in Saudi Arabia• Nahdi Medical Company, Al-Dawaa Medical Services, SPIMACO, Jamjoom Pharma, Tabuk Pharmaceuticals, Almarai, Nestlé, Abbott, Danone, Nature's Bounty, Solgar (Nestlé Health Science), Centrum (Haleon), Jamieson Wellness, and Nordic Naturals are leading players in the Saudi EPA & DHA market, offering finished supplements, prescription medicines, DHA-fortified infant formula, and retail distribution. Their strong presence, extensive pharmacy networks, halal-compliant product ranges, and relationships with healthcare professionals have driven adoption across the Saudi market.• The market is also supported by regional distributors, contract manufacturers, logistics providers, and e-commerce platforms that provide import, registration, and distribution support. With Vision 2030 driving healthcare and industrial localization, Saudi Arabia is positioned to become the largest omega-3 market in the GCC.Saudi Arabia EPA & DHA Supply and Pricing Economics• EPA and DHA products in Saudi Arabia represent largely imported nutritional products whose pricing depends on brand origin, concentration, source, halal certification, and channel. Pricing varies considerably between mass-market fish oil, premium international brands, krill oil, and algal oil.• Retail pricing is influenced by import costs, SFDA registration requirements, and global raw material prices. The reduced 2026 Peruvian anchovy quota is expected to place renewed upward pressure on fish oil prices.• Supplements are largely paid out-of-pocket, while prescription omega-3 medicines may be provided through government healthcare facilities for nationals and covered by mandatory health insurance for eligible expatriates.• Local manufacturing under Vision 2030 is expected to gradually reduce costs and improve availability of domestically produced omega-3 products.Market Outlook by Consumer Health Spending and Supply Infrastructure• Saudi Arabia's EPA & DHA market growth is strongly linked to population growth, Vision 2030 healthcare transformation, and the expansion of pharmacy and e-commerce channels, although import dependence and registration requirements remain significant factors influencing market entry and pricing.• Private consumer spending drives the supplement and pet nutrition segments, while government healthcare and mandatory insurance support access to prescription omega-3.

Large pharmacy chains continue to expand omega-3 visibility through private labels and promotions.• The future growth opportunity for EPA and DHA in Saudi Arabia depends on preventive health initiatives under Vision 2030, local manufacturing expansion, implementation of updated fortification and infant formula standards, and consumer education on the omega-3 intake gap. Greater integration of omega-3 within chronic disease prevention and maternal and child health programs will likely support long-term market development.Global EPA & DHA MarketConsidered in this report• Historic Year: 2020• Base Year: 2025• Estimated Year: 2026• Forecast Year: 2031Aspects covered in this report• EPA & DHA Market with its value and forecast along with its segments• Various drivers and challenges• Ongoing trends and developments• Top profiled companies• Strategic recommendationsBy Product Type• Eicosapentaenoic Acid (EPA)• Docosahexaenoic Acid (DHA)By Application• Dietary Supplements• Infant Formula• Pharmaceuticals• Food & Beverages• Clinical Nutrition & Medical Foods• Pet NutritionBy Source• Fish Oil• Algae Oil• Krill Oil• Other Marine Sources.